A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.

[1]  B. Overmoyer.  Chemotherapeutic palliative approaches in the treatment of breast cancer. , 1995, Seminars in oncology.

[2]  R. Blamey,et al.  Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? , 1993, British Journal of Cancer.

[3]  C. Twelves,et al.  Breast cancer and liver metastases--incidence, diagnosis and outcome. , 1992, Journal of the Royal Society of Medicine.

[4]  C. Spurr,et al.  Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. , 1991, The New England journal of medicine.

[5]  J. Carmichael,et al.  Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer , 1990, The Lancet.

[6]  M. Tattersall,et al.  Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.

[7]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[8]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[9]  A. Bartolucci,et al.  Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. , 1976, Cancer research.

[10]  S. Pocock,et al.  Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L‐phenylalanine mustard , 1976, Cancer.

[11]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[12]  H. Mouridsen,et al.  Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. , 1993, European journal of cancer.